A Double‐blind Placebo‐controlled Cross‐over Study with Lidoflazine (Clinium®) in Post‐infarction Patients

Publisher Website
Google Scholar
Abstract
The effects of lidoflazine were studied on exercise tolerance during a double-blind cross-over trial in 14 male post-infarction patients with a median age of 47 yr (range 24-58). Each treatment phase lasted 3 mo. Lidoflazine dosage was one 60 mg tablet 3 times daily. At rest, significant decreases in diastolic blood pressure (DBP) and heart rate (HR) were noted during lidoflazine treatment. Bicycle ergometric tests revealed a significant increase in maximum work load and a significant decrease in the product HR .times. systolic BP [blood pressure] at a 100 W work load during lidoflazine. No similar changes were recorded during placebo periods. Five patients resumed their professional activities while on lidoflazine, against only 2 on placebo.